Abstract: The current invention relates to a method of separating polyunsaturated fatty acids containing lipids from a lipids containing biomass.

Abstract: Disclosed herein is a permanent magnet comprising: a plurality of aligned iron nitride nanoparticles wherein the iron nitride nanoparticles include ??-Fe16N2 phase domains; wherein a ratio of integrated intensities of an ??-Fe16N2 (004) x-ray diffraction peak to an ??-??-Fe16N2 (202) x-ray diffraction peak for the aligned iron nitride nanoparticles is greater than at least 7%, wherein the diffraction vector is parallel to alignment direction, and wherein the iron nitride nanoparticles exhibit a squareness measured parallel to the alignment direction that is greater than a squareness measured perpendicular to the alignment direction.

Abstract: Disclosed herein is a permanent magnet comprising: a plurality of aligned iron nitride nanoparticles wherein the iron nitride nanoparticles include ??-Fe16N2 phase domains; wherein a ratio of integrated intensities of an ??-Fe16N2 (004) x-ray diffraction peak to an ??-??-Fe16N2 (202) x-ray diffraction peak for the aligned iron nitride nanoparticles is greater than at least 7%, wherein the diffraction vector is parallel to alignment direction, and wherein the iron nitride nanoparticles exhibit a squareness measured parallel to the alignment direction that is greater than a squareness measured perpendicular to the alignment direction.

Abstract: This invention provides a compound having the structure wherein ?, ?, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NFK-B activation in a population of cells.

Abstract: This invention provides a compound having the structure wherein ?, ?, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF?-B activation in a population of cells.

Abstract: A method of manipulating microdroplets having an average volume in the range 0.5 femtolitres to 10 nanolitres comprised of at least one biological component and a first aqueous medium having a water activity of aw1 of less than 1 is provided. It is characterised by the step of maintaining the microdroplets in a water-immiscible carrier fluid which further includes secondary droplets having an average volume less than 25% of the average volume of the microdroplets up to and including a maximum of 4 femtolitres and wherein the volume ratio of carrier fluid to total volume of microdroplets per unit volume of the total is greater than 2:1. The method may be employed for example with microdroplets containing biological cells or with microdroplets containing single nucleoside phosphate such as are prepared in a droplet-based nucleic acid sequencer.

Abstract: A method of manipulating microdroplets having an average volume in the range 0.5 femtolitres to 10 nanolitres comprised of at least one biological component and a first aqueous medium having a water activity of aw1 of less than 1 is provided. It is characterised by the step of maintaining the microdroplets in a water-immiscible carrier fluid which further includes secondary droplets having an average volume less than 25% of the average volume of the microdroplets up to and including a maximum of 4 femtolitres and wherein the volume ratio of carrier fluid to total volume of microdroplets per unit volume of the total is greater than 2:1. The method may be employed for example with microdroplets containing biological cells or with microdroplets containing single nucleoside phosphate such as are prepared in a droplet-based nucleic acid sequencer.

Abstract: Disclosed herein is a permanent magnet comprising: a plurality of aligned iron nitride nanoparticles wherein the iron nitride nanoparticles include ??-Fe16N2 phase domains; wherein a ratio of integrated intensities of an ??-Fe16N2 (004) x-ray diffraction peak to an ??-??-Fe16N2 (202) x-ray diffraction peak for the aligned iron nitride nanoparticles is greater than at least 7%, wherein the diffraction vector is parallel to alignment direction, and wherein the iron nitride nanoparticles exhibit a squareness measured parallel to the alignment direction that is greater than a squareness measured perpendicular to the alignment direction.

Abstract: Iron nitride nanoparticles and magnet materials made from iron nitride nanoparticles are described. The iron nitride nanoparticles have a core and a shell morphology. The shell is configured to provide a means to nitride the core. The magnetic materials are characterized as having an Msat greater than about 160 emu/g and a coercivity greater than about 700 Oe.

Abstract: Disclosed herein is a permanent magnet comprising: a plurality of aligned iron nitride nanoparticles wherein the iron nitride nanoparticles include ??-Fe16N2 phase domains; wherein a ratio of integrated intensities of an ??-Fe16N2 (004) x-ray diffraction peak to an ??-??-Fe16N2 (202) x-ray diffraction peak for the aligned iron nitride nanoparticles is greater than at least 7%, wherein the diffraction vector is parallel to alignment direction, and wherein the iron nitride nanoparticles exhibit a squareness measured parallel to the alignment direction that is greater than a squareness measured perpendicular to the alignment direction.

Abstract: A method of manipulating microdroplets having an average volume in the range 0.5 femtolitres to 10 nanolitres comprised of at least one biological component and a first aqueous medium having a water activity of aw1 of less than 1 is provided. It is characterised by the step of maintaining the microdroplets in a water-immiscible carrier fluid which further includes secondary droplets having an average volume less than 25% of the average volume of the microdroplets up to and including a maximum of 4 femtolitres and wherein the volume ratio of carrier fluid to total volume of microdroplets per unit volume of the total is greater than 2:1. The method may be employed for example with microdroplets containing biological cells or with microdroplets containing single nucleoside phosphate such as are prepared in a droplet-based nucleic acid sequencer.

Abstract: A method of increasing production of one or more lipoxins in a subject in need thereof comprising administering to the subject an amount of a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, so as to thereby increase production of the one or more lipoxins in the subject.

Abstract: Disclosed herein is a permanent magnet comprising: a plurality of aligned iron nitride nanoparticles wherein the iron nitride nanoparticles include ??-Fe16N2 phase domains; wherein a ratio of integrated intensities of an ??-Fe16N2 (004) x-ray diffraction peak to an ??-??-Fe16N2 (202) x-ray diffraction peak for the aligned iron nitride nanoparticles is greater than at least 7%, wherein the diffraction vector is parallel to alignment direction, and wherein the iron nitride nanoparticles exhibit a squareness measured parallel to the alignment direction that is greater than a squareness measured perpendicular to the alignment direction.

Abstract: A method of heat-treating an additively-manufactured ferromagnetic component is presented and a related ferromagnetic component is presented. A saturation flux density of a heat-treated ferromagnetic component is greater than a saturation flux density of an as-formed ferromagnetic component. The heat-treated ferromagnetic component is further characterized by a plurality of grains such that at least 25% of the plurality of grains have a median grain size less than 10 microns and 25% of the plurality of grains have a median grain size greater than 25 microns.

Abstract: A turbine apparatus is disclosed including a first article and a second article disposed between the first article and a hot gas path of a turbine. The first article includes at least one first article cooling channel in fluid communication with and downstream from a cooling fluid source, and the second article includes at least one second article cooling channel in fluid communication with and downstream from the at least one first article cooling channel. A method for redundant cooling of the turbine apparatus is disclosed including flowing a cooling fluid from the cooling fluid source through at least one first article cooling channel, exhausting the cooling fluid from the at least one first article cooling channel into at least one second article cooling channel, and flowing the cooling fluid through the at least one second article cooling channel.

Abstract: A method of heat-treating an additively-manufactured ferromagnetic component is presented and a related ferromagnetic component is presented. A saturation flux density of a heat-treated ferromagnetic component is greater than a saturation flux density of an as-formed ferromagnetic component. The heat-treated ferromagnetic component is further characterized by a plurality of grains such that at least 25% of the plurality of grains have a median grain size less than 10 microns and 25% of the plurality of grains have a median grain size greater than 25 microns.

Abstract: This invention provides a compound having the structure wherein ?, ?, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF?-B activation in a population of cells.

Abstract: A magnetic component having a unitary structure, a transverse flux electric machine having the magnetic component, and a method of making the magnetic component are disclosed. The unitary structure of the magnetic component includes a magnetic region and a non-magnetic region. The magnetic region includes a magnetic phase and an electrically insulating phase. The non-magnetic region includes a non-magnetic phase. The magnetic phase includes a metallic material and the non-magnetic phase includes a nitrogenated metallic material formed by a controlled nitrogenation of the metallic material.

Abstract: The present invention is directed to composite nanoparticles comprising a metal, a rare earth element, and, optionally, a complexing ligand. The invention is also directed to composite nanoparticles having a core-shell structure and to processes for preparation of composite nanoparticles of the invention.